Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of GLPG3667 in Healthy Male Subjects
NCT04097938Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Sep 2019
- Primary completion
- Mar 2020
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cadefrecitinib in psoriasis, dermatomyositis (DM) and systemic lupus erythematosus (SLE) (7 arms), sponsored by Galapagos NV. Primary endpoint: Treatment-emergent adverse events at 5 months. Started Sep 2019; status: completed.
02
Drugs
cadefrecitinib
03
Conditions
psoriasisdermatomyositis (DM)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04097938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04097938.